BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 24, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 25, 2012
View Archived Issues
New MMP inhibitors designed
Read More
Scientists in Germany patent novel HSP 90 inhibitors
Read More
Merck & Co. prepares novel HCV inhibitors
Read More
New transient receptor potential TRPM8 channel antagonists patented
Read More
Novel phosphodiesterase 10A inhibitors presented by Merck & Co.
Read More
Novel histamine H4 receptor ligands designed in France
Read More
Enanta presents novel antiviral with excellent cross-resistance profile
Read More
New Roche oncolytic targets chondroitin sulfate proteoglycan 4
Read More
BAF-312 dose titration reduces bradyarrhythmic events in phase II trial
Read More
Phase I data encourage advancement of candidate MS drug to phase II
Read More
MicroDose Therapeutx completes phase I studies of MDT-637
Read More
Omontys launched in U.S.
Read More
Alimera announces first marketing authorization for Iluvien in E.U.
Read More
Bayer expands BiTE antibody collaboration
Read More
Recruitment complete in phase II studies of Levulan Kerastick PDT
Read More
New Presidio product shows promise to treat hepatitis
Read More
Nordion plans new phase III TheraSphere trial
Read More
Summit clear to conduct phase I trial of SMT-C1100
Read More
Adocia reports phase II results for diabetic foot ulcer treatment
Read More
Nanobody for Alzheimer's disease advances toward phase I trials
Read More
NICE issues final guidance on new hepatitis C drugs
Read More
Recommendations issued for treatment of first-line chronic myeloid leukemia
Read More
NICE recommends NHS provide Gilenya in relapsing-remitting MS
Read More
Hisamitsu reports on HTU-520 study
Read More
First medicine approved in E.U. for Cushing's disease
Read More
